Une bonne gouvernance d’entreprise est l'origine de la confiance que nous accordent nos investisseurs, les institutions et nos salariés. Valneva s'attache à maintenir cette confiance à mesure que la société grandit.

Directoire

Le directoire de Valneva est une équipe internationale et dévouée cumulant expériences, expertises et compétences multiples.

Thomas Lingelbach Président et Chief Executive Officer, Président du Directoire

Thomas Lingelbach was CEO of Intercell and founding CEO of Valneva.

He is an established vaccine industry leader with breadth of experience. Prior to Valneva Thomas had senior & executive management roles with Intercell, Novartis and Chiron.

During his 30 years in vaccines, he held a variety of positions from product development to commercialization with a strong emphasis on technical development & operations.

In different capacities, he contributed to the successful development and licensure of more than ten vaccines.

Thomas Lingelbach holds an engineering degree, specialized in bioprocess engineering and complemented his education with a business administration program.

He is a German national, born in 1963.

Franck Grimaud Directeur Général & Chief Business Officer

Franck Grimaud was co-founder, President & CEO of Vivalis and co-led its merger with Intercell to create Valneva.

He has a long-standing and proven track record in strategic, corporate and business development management, with more than 23 years in the biotech industry.

Prior to creating and successfully building Vivalis as a French public biotech company, he was responsible for the creation of the Asian subsidiaries of Groupe Grimaud, a leader in animal genetic selection and currently Valneva’s largest shareholder.

Franck Grimaud holds an MBA.

He is a French national, born in 1966.

Peter Bühler Chief Financial Officer, Directeur Financier

Peter joined Valneva as CFO in early 2022.

He has over 20 years of experience in the strategic and financial leadership of life science and technology companies.

Before joining Valneva, he served as CFO of Nasdaq-listed Swiss diagnostics company Quotient. He also served as Group CFO of Zaluvida AG and as Group CFO of Stallergenes Greer Plc, where he led a complex merger project to combine a French and U.S. company.

Prior to this, Peter held senior finance roles at Eli Lilly, Merck Serono and Logitech.

He is a Swiss Certified Accountant and holds an executive MBA.

Peter is a Swiss national, born in 1969.

Juan Carlos Jaramillo, MD Chief Medical Officer, Directeur Médical

Dr. Juan Carlos Jaramillo joined Valneva in October 2020.

He is an experienced R&D leader with a broad expertise in medical affairs, clinical development including vaccines, as well as market access and pricing.

During his more than 20 years in the pharmaceutical industry and prior to joining Valneva, he held senior management roles with Daiichi Sankyo, Grünenthal and GlaxoSmithKline.

Due to his diverse pharma exposure, he has an in-depth business understanding and a strong track record of success across a wide range of settings, therapeutic areas and geographies.

Juan Carlos Jaramillo is a Medical Doctor.

He was born in 1970 in Colombia, raised and educated in the US and holds U.S. citizenship.

Frederic Jacotot General Counsel, Directeur Juridique

Frederic Jacotot joined Valneva as VP Legal & IP and General Counsel shortly after the creation of the Company, and joined the Management Board in April 2017.

He is an established legal expert in the pharmaceutical industry.

During his 30 years in the business he has held a variety of positions with increasing responsibilities and, prior to Valneva, served as Division Counsel at Abbott.

Frederic holds a Master’s degree in business law from Paris 1 University.

He is a French national, born in 1964.

Conseil de surveillance

Faisant partie de son système de gouvernance, le Conseil de surveillance de Valneva participe activement à l'étude des options stratégiques du Groupe et définit l'orientation de la société avec le directoire.

Frédéric Grimaud (F)

Président du conseil de surveillance de Valneva, Représentant de l'actionnaire majoritaire du Groupe, Président du Groupe Grimaud.

James Sulat (U.S.)

Membre du Conseil de surveillance et Président du Comité d'audit et de gouvernance, Ancien Directeur financer de Chiron et CEO de Maxygen.

Anne-Marie Graffin (F)

Membre du Conseil de surveillance, Managing Director de SMAG Consulting, Membre du conseil de surveillance de Nanobiotix SA, Membre du Board de Sartorius Stedim Biotech SA, Ancien Vice-Président chez Sanofi Pasteur MSD.

Sharon Tetlow (U.S.)

Membre du Conseil de surveillance, Fondatrice et Managing Partner de Potrero Hill Advisors, Membre du Conseil d’administration et Présidente du Comité d’audit de Catalyst Biosciences (NASDAQ:CBIO).

Johanna Willemina Pattenier (CH)

Membre du Conseil de surveillance, General Manager de la division vaccin de Novartis, Novartis Vaccines and Diagnostics (aujourd’hui société de GlaxoSmithKline - GSK). Mme Pattenier a exercé différents rôles commerciaux et médicaux au niveau international chez GSK, Organon et Byk Gulden.

James Edward Connolly (US)

Membre du Conseil de Surveillance, Plus de trois décennies d'expérience dans l'industrie des sciences de la vie. Ancien vice-président exécutif et directeur général de Wyeth Vaccines et président de Wyeth Canada

Maïlys Ferrère for Bpifrance (FR)

Membre du Conseil de Surveillance, directrice des investissements à haut risque chez Bpifrance, ancienne directrice des investissements du Fonds Stratégique d'Investissement

Conseil Scientifique

En juillet 2019, Valneva a annoncé la création d’un Conseil Scientifique (SAB) dans le cadre de l’évolution de sa structure de gouvernance.

Dr. Ralf Clemens, MD, Ph.D. Président du Conseil Scientifique

Member of Board of Trustees International Vaccine Institute IVI, member GHIT scientific selection committee, Advisor Bill & Melinda Gates Foundation, former Head/Senior Vice President Vaccine Development at GSK, Novartis and Takeda

Dr. Norman W. Baylor, Ph.D.

President and CEO of Biologics Consulting, Temporary Advisor to the World Health Organization; Former Director of the US FDA Office of Vaccines Research and Review; Former FDA Liaison to the Centers for Disease Control’s Advisory Committee on Immunization Practices

Dr. Thomas Decker

Professeur d'immunobiologie au sein du laboratoire Max Perutz de l'Université de Vienne; Président de la « European Macrophage and Dendritic Cell Society (EMDS); Membre des comités de rédaction des revues scientifiques Molecular and Cellular Biology et Journal of Biological Chemistry.

Dr. Anna Durbin, MD

Professor of International Health at the Johns Hopkins Bloomberg School of Public Health, Principal Investigator at the Center for Immunization Research

Alexander von Gabain

Co-founder of Intercell and member of Valneva’s SAB. He is also holding an observer seat on Valneva’s Supervisory Board. Furthermore, he is serving in the SAB of the Paul Ehrlich Institute, Frankfurt and in the Board of Trustees of the Institute of Science and Technology, Austria. He is Vice-President off duty at the Karolinska Intitutet, Stockholm.

Dr. Michael Pfleiderer, Ph.D.

Expert de renommée internationale en matière d'affaires réglementaires et de développement de vaccins; Depuis 1998, le Dr Pfleiderer dirigeait la section des vaccins viraux humains de l’Institut Paul Ehrlich (PEI), l'Institut fédéral allemand pour les vaccins et les biomédicaments.

Dr. George R. Siber, MD, PhD

Adjunct Professor of Medicine at Johns Hopkins University, Co-founder and Board Member of Affinivax, Board Member of Genocea, former Supervisory Board Member of Crucell and former Executive Vice President and CSO of Wyeth Vaccines